Contraception in the perimenopause

Menopause International

Volumn 9, Issue 3, 2003, Pages 123-128

  Gebbie, Ailsa ^a  

^a Dean Terrace Centre   (United Kingdom)

Author keywords

Contraception; fertility; hormone replacement therapy; perimenopause; pregnancy

Indexed keywords

DESOGESTREL; ETONOGESTREL; GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT;

ACCURACY; AMENORRHEA; ARTERY DISEASE; BREAST CANCER; CARDIOVASCULAR DISEASE; CLIMACTERIUM; CLINICAL TRIAL; CONDOM; CONTRACEPTION; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FEMALE STERILITY; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; MENOPAUSAL SYNDROME; MENSTRUAL IRREGULARITY; MENSTRUATION DISORDER; ORAL CONTRACEPTION; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SEXUAL FUNCTION; SIDE EFFECT; SMOKING HABIT; SUBFERTILITY; THROMBOEMBOLISM; UTERINE CERVIX CANCER;

CLIMACTERIC; CONTRACEPTION; CONTRACEPTIVES, ORAL, COMBINED; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS;

EID: 84990380749     PISSN: 17540453     EISSN: None     Source Type: Journal    
DOI: 10.1177/136218070300900311     Document Type: Review

References (49)

1. Dunson DB, Colombo B, Baird DD. Changes with age in the level and duration of fertility in the menstrual cycle. Hum Reprod 2002; 17: 1399–1403.
2. Stovall DW, Toma SK, Hammond MG. The effect of age on female fecundity. Obstet Gynecol 1991; 77: 33–36.
3. Gosden R, Rutherford A. Delayed childbearing. BMJ 1995; 311: 1585.
4. Ruess ML, Kline J, Santos R, et al. Age and the ovarian follicle pool assessed with transvaginal ultrasonography. Am J Obstet Gynecol 1996; 174: 624–627.
5. The Guinness book of Records. Guinness Media Inc, ed. Guinness World Records Limited, London, Bantam books. 2000.
6. Office for National Statistics. Population trends. The Stationary Office. London. Spring 1997; 87: 17.
7. Maroulis GB. Effect of ageing on fertility and pregnancy. Semin Reprod Endocrinol 1991; 3: 165–175.
8. Spellacy WN, Miller SL, Winegar A. Pregnancy after 40 years of age. Obstet Gynecol 1986; 83: 452–454.
9. Johnson A, Wadsworth J. Heterosexual practices. In Wellings K, Field J, Johnson A, eds. Sexual behaviour in Britain. The national survey of sexual attitudes and lifestyles, pp 133–177. London: Penguin Books, 1995.
10. Bancroft J. Sexuality and Family Planning. In Glasier A, Gebbie A, eds. Handbook of Family Planning, pp 313–334. Edinburgh: Churchill Livingstone, 2000.
11. Schering Healthcare Consumer Study 1999 (data on file – personal communication).
12. Toulemon L, Leridon H. Contraceptive practice and trends in France. Family Planning Perspectives 1998; 30: 114–120.
13. Oddens BJ, Visser AP, Vemer HM, et al. Contraceptive use and attitudes in Great Britain. Contraception 1994; 49: 73–86.
14. Beral V, Hermon C, Kay C, et al. Mortality associated with oral contraceptive use: 25 year follow up of cohort of 46,000 women from the Royal College of General Practitioners' oral contraception study. BMJ 1999; 318: 96–100.
15. World Health Organization. Improving access to quality care in Family Planning. Medical Eligibility Criteria for Contraceptive Use. WHO/FRH/FPP/96.9. Geneva, 1996.
16. World Health Organisation. Cardiovascular disease and use of oral and injectable progestogen-only contraceptive and combined injectable contraceptives. Results of an international multicentre, case-control study. Contraception 1998; 57: 315–324.
17. Jick H, Kaye JA, Vasilakis-Scaramozza C Jick S. Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis. BMJ 2000; 321: 1190–1195.
18. Collaborative Group on Hormonal Factors in Breast Cancer. Breast Cancer and Hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100, 239 women without breast cancer from 543 epidemiological studies. Lancet 1996; 347: 1717–1727.
19. Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and risk of breast cancer. N Engl J Med 2002; 346: 2025–2032.
20. Smith JS, Green J, Berrington de Gonzalez A, et al. Cervical cancer and use of hormonal contraceptives; a systemic review. Lancet 2003; 361: 1159–1163.
21. Francheschi S. Oral contraceptive use and risk of cancer of the ovary and corpus uteri. In Hannaford PC, Webb AMC, eds. Evidence-guided prescribing of the pill. pp 135–144. Camforth: Parthenon Publishing Group, 1996
22. Martinez ME, Grondstein F, Giovannucci E, et al. A prospective study of reproductive factors, oral contraceptive use, and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 1997; 6: 1–5.
23. Brinton LA, Vessey MP, Flavel R, et al. Risk factors for benign breast disease. Am J Epidemiol 1981; 113: 203–214.
24. Lanes SF, Birmann B, Walker AM, et al. Oral contraceptive type and functional ovarian cysts. Am J Obstet Gynecol 1992; 166: 956–961.
25. Larsson G, Milson I, Lindstedt G, Rybo G. The influence of low-dose combined oral contraception on menstrual blood loss and iron status. Contraception 1992; 46: 327–334.
26. Vessey M, Painter R, Mant J. Oral contraception and other factors in relation to hospital referral for menstrual problems without known underlying cause: findings in a large cohort study. Br J Fam Plann 1996; 22: 166–169.
27. Kunhong W, Borgatta L, Stubblefield P. Low dose oral contraceptives and bone mineral density: an evidence base analysis. Contraception 2000; 61: 77–82.
28. Vessey MP, Lawless M, Yeats D, McPherson K. Progestogen-only oral contraception. Findings in a large prospective study with special reference to effectiveness. Br J Fam Plann 1985; 10: 117–121.
29. Rice CF, Killick SR, Dieben T, Coelingh Bennink H. A comparison of the inhibition achieved by desogestrel 75 μg and levonorgestrel 30 μg daily. Hum Reprod 1999; 14: 982–985.
30. Vessey M, Painter R. Oral contraceptive failures and body weight: findings in a large cohort study. J Fam Plann and Reprod Health Care 2001; 27: 90–91.
31. Tang OS, Tang G, Yip P, et al. Long term depot-medroxyprogesterone acetate and bone mineral density. Contraception 1999; 59: 25–29.
32. Orr-Walker BJ Evans MC Ames RW, et al. The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal postmenopausal women. Clin Endocrinol 1998; 49: 615–618.
33. Cundy T, Cornish J, Evans MC, et al. Recovery of bone density in women who stop using medroxyprogesterone acetate. BMJ 1994; 308: 247–248.
34. Edwards JE, Moore A. Implanon – a review of clinical studies. Br J Fam Plann 1999; 24(Suppl 4): 3–16.
35. Webb AM. Emergency contraception. BMJ 2003; 326: 775–776.
36. Chi I-C. What we have learned from recent IUD studies: a researcher's perspective. Contraception 1993; 48: 81–108.
37. Kazuh-Novak M Andolesk L. IUD use after 40 years of age. Adv Contracept 1988; 4: 85–89.
38. Tacchi D. Long term use of copper intra-uterine devices. Lancet 1991; 336: 182.
39. Andersson K, Rybo G. Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia. Br J Obstet Gynaecol 1990; 97: 690–694.
40. Hurskainen R, Teperi J, Rissanen P, et al. Quality of life and cost-effectiveness of levonorgestrel-releasing intrauterine system versus hysterectomy for treatment of menorrhagia: a randomised trial. Lancet 2001; 357: 273–277.
41. Andersson K, Mattsson L-A Rybo G. Intrauterine release of levonorgestrel; a new way of adding progestogen in hormone replacement therapy. Am J Obstet Gynecol 1992; 79: 963–967.
42. Radoskoski T, Lahti E, Kauppila A, et al. Transdermal oestrogen with a levonorgestrel-releasing intrauterine device for climacteric symptoms. Am J Obstet Gynecol 1995; 172: 114–119.
43. Riphagen FE. Intrauterine application of progestins in hormone replacement therapy; a review. Climacteric 2000; 3: 199–212.
44. Radoskoski T, Tapanainen J, Tomas E, et al. Intrauterine 10ug and 20ug levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response. Br J Obstet Gynaecol 2002; 109: 136–144.
45. Bounds W. Contraceptive efficacy of the diaphragm and cervical caps use in conjunction with a spermicide. A fresh look at the evidence. Br J Fam Plann 1994; 20: 84–87.
46. Hillis SD, Marchbanks PA, Tylor LR, Peterson HB. Poststerilization regret: findings from the United States review of sterilisation. Obstet Gynecol 1999; 93: 889–895.
47. Gebbie A. Menopause. In Glasier A, Gebbie A, eds. Handbook of family planning and reproductive health care, pp 371–394, Edinburgh: Churchill Livingstone, 2000.
48. Castracane VD, Gimpel R, Goldzieher JW. When is it safe to switch from oral contraceptives to hormonal replacement therapy? Contraception 1995; 52: 371–376.
49. Gebbie A, Glasier A, Sweeting V. Incidence of ovulation in perimenopausal women before and during hormone replacement therapy. Contraception 1995; 52: 221–222.